Linklaters advises arranging banks on the financing of Nestle Skin Health’s acquisition by a consortium led by EQT and the Abu Dhabi Investment Authority

  • Largest leveraged buyout in the European market this year
  • Second largest since the financial crisis

Linklaters has advised the arranging banks on the financing of the acquisition of Nestle Skin Health by a consortium led by EQT Private Equity and the Abu Dhabi Investment Authority (ADIA).  Valued at an enterprise value of CHF10.2 billion, it was financed with equity and debt, with the debt component comprised of USD 2.5 billion and EUR 971 million term loan B facilities and a USD 500 million revolving credit facility.

The transaction is reportedly the largest leveraged buyout in the European market this year and the second largest since the financial crisis.

Nestlé Skin Health provides science-based solutions to meet the specific skin health needs of healthcare professionals, patients and consumers. It offers a range of leading medical and consumer brands through three complementary business units in prescription, aesthetics and consumer care. 

Headquartered in Lausanne, Switzerland, Nestlé Skin Health employs more than 5,000 people across 40 countries.

The Linklaters London based team working on the transaction were led by our partners Adam Freeman and Robert Burt, our managing associate Julia Stapelfeld and our associate James Ashcroft.